JP2013528655A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528655A5
JP2013528655A5 JP2013515492A JP2013515492A JP2013528655A5 JP 2013528655 A5 JP2013528655 A5 JP 2013528655A5 JP 2013515492 A JP2013515492 A JP 2013515492A JP 2013515492 A JP2013515492 A JP 2013515492A JP 2013528655 A5 JP2013528655 A5 JP 2013528655A5
Authority
JP
Japan
Prior art keywords
compound according
compound
xanthine oxidase
oxidase inhibitor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013515492A
Other languages
English (en)
Japanese (ja)
Other versions
JP5551310B2 (ja
JP2013528655A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/040585 external-priority patent/WO2011159839A2/en
Publication of JP2013528655A publication Critical patent/JP2013528655A/ja
Publication of JP2013528655A5 publication Critical patent/JP2013528655A5/ja
Application granted granted Critical
Publication of JP5551310B2 publication Critical patent/JP5551310B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013515492A 2010-06-16 2011-06-15 チオ酢酸化合物、組成物、および、その使用方法 Active JP5551310B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35549110P 2010-06-16 2010-06-16
US61/355,491 2010-06-16
PCT/US2011/040585 WO2011159839A2 (en) 2010-06-16 2011-06-15 Thioacetate compounds, compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014105611A Division JP5768166B2 (ja) 2010-06-16 2014-05-21 チオ酢酸化合物、組成物、および、その使用方法

Publications (3)

Publication Number Publication Date
JP2013528655A JP2013528655A (ja) 2013-07-11
JP2013528655A5 true JP2013528655A5 (enExample) 2014-05-15
JP5551310B2 JP5551310B2 (ja) 2014-07-16

Family

ID=45348850

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013515492A Active JP5551310B2 (ja) 2010-06-16 2011-06-15 チオ酢酸化合物、組成物、および、その使用方法
JP2014105611A Active JP5768166B2 (ja) 2010-06-16 2014-05-21 チオ酢酸化合物、組成物、および、その使用方法
JP2015120633A Active JP6112318B2 (ja) 2010-06-16 2015-06-15 チオ酢酸化合物、組成物、および、その使用方法
JP2017035549A Active JP6364515B2 (ja) 2010-06-16 2017-02-27 チオ酢酸化合物、組成物、および、その使用方法
JP2018123691A Pending JP2018168174A (ja) 2010-06-16 2018-06-28 チオ酢酸化合物、組成物、および、その使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014105611A Active JP5768166B2 (ja) 2010-06-16 2014-05-21 チオ酢酸化合物、組成物、および、その使用方法
JP2015120633A Active JP6112318B2 (ja) 2010-06-16 2015-06-15 チオ酢酸化合物、組成物、および、その使用方法
JP2017035549A Active JP6364515B2 (ja) 2010-06-16 2017-02-27 チオ酢酸化合物、組成物、および、その使用方法
JP2018123691A Pending JP2018168174A (ja) 2010-06-16 2018-06-28 チオ酢酸化合物、組成物、および、その使用方法

Country Status (41)

Country Link
US (5) US10266493B2 (enExample)
EP (5) EP3611167A1 (enExample)
JP (5) JP5551310B2 (enExample)
KR (2) KR101432950B1 (enExample)
CN (2) CN103864677B (enExample)
AR (1) AR081930A1 (enExample)
AU (1) AU2011268360B2 (enExample)
BR (1) BR112012032028B1 (enExample)
CA (1) CA2802535C (enExample)
CL (1) CL2012003546A1 (enExample)
CO (1) CO6640311A2 (enExample)
CR (1) CR20120649A (enExample)
CU (1) CU24126B1 (enExample)
CY (1) CY1120337T1 (enExample)
DK (3) DK2712861T3 (enExample)
DO (1) DOP2012000314A (enExample)
EA (1) EA022933B1 (enExample)
EC (1) ECSP12012353A (enExample)
ES (3) ES2459146T3 (enExample)
GT (1) GT201200339A (enExample)
HN (1) HN2012002664A (enExample)
HR (3) HRP20140391T1 (enExample)
HU (2) HUE025962T2 (enExample)
IL (2) IL223435A (enExample)
LT (1) LT2975025T (enExample)
ME (2) ME01830B (enExample)
MX (2) MX2012014863A (enExample)
MY (1) MY153039A (enExample)
PE (1) PE20131047A1 (enExample)
PH (1) PH12012502460A1 (enExample)
PL (3) PL2975025T3 (enExample)
PT (3) PT2975025T (enExample)
RS (3) RS54375B1 (enExample)
SG (2) SG186298A1 (enExample)
SI (3) SI2975025T1 (enExample)
SM (3) SMT201800304T1 (enExample)
TR (1) TR201808344T4 (enExample)
TW (2) TWI460173B (enExample)
UA (1) UA107115C2 (enExample)
WO (1) WO2011159839A2 (enExample)
ZA (1) ZA201209574B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
BR112012032193A2 (pt) 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
CA2852490A1 (en) * 2011-11-03 2013-05-10 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound to reduce serum uric acid levels
PE20150974A1 (es) 2012-11-14 2015-07-04 Teijin Pharma Ltd Derivados de piridina
HUE037512T2 (hu) 2013-05-13 2018-08-28 Shanghai hengrui pharmaceutical co ltd Cikloalkilsav-származék, eljárás elõállítására, és felhasználása gyógyszerként
JP6322704B2 (ja) * 2013-06-27 2018-05-09 エルジー・ケム・リミテッド Gpr120アゴニストとしてのビアリール誘導体
AU2015260300A1 (en) 2014-05-13 2016-12-22 Teijin Pharma Limited Pyrazine derivative
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技(上海)有限公司 羧酸化合物及其制备方法和用途
CN115925679A (zh) * 2014-12-24 2023-04-07 株式会社Lg化学 作为gpr120激动剂的联芳基衍生物
RU2721844C2 (ru) * 2014-12-29 2020-05-25 Ниппон Кемифар Ко., Лтд. Ингибиторы urat1
WO2017028762A1 (zh) * 2015-08-14 2017-02-23 广东东阳光药业有限公司 一种萘环化合物的晶型
CN105418495B (zh) * 2015-11-25 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 一种硫醚的制备方法
WO2017097182A1 (zh) * 2015-12-07 2017-06-15 成都海创药业有限公司 喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途
SG11201804100UA (en) * 2015-12-08 2018-06-28 Ardea Biosciences Inc Pharmaceutical composition comprising a potent inhibitor of urat1
JP6898330B2 (ja) * 2015-12-28 2021-07-07 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド インドリジン誘導体、組成物、及び使用方法
WO2017121308A1 (en) * 2016-01-11 2017-07-20 Chongqing Fochon Pharmaceutical Co., Ltd. Fused pyridine compounds, compositions and methods of use
JP6971997B2 (ja) * 2016-02-15 2021-11-24 アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・(インセルム) 個体における尿中シュウ酸塩濃度を低下させるための、スチリペントール及びその誘導体の使用
CN105884807A (zh) * 2016-04-26 2016-08-24 昆药集团股份有限公司 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法
CN106117130A (zh) * 2016-06-28 2016-11-16 昆药集团股份有限公司 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
CN110121359A (zh) 2016-11-11 2019-08-13 怀特黑德生物制剂研究所 人血浆培养基
CN106748987B (zh) * 2016-11-18 2019-05-31 昆药集团股份有限公司 2-((3-(4-氰基萘-1-基)吡啶-4-基)硫基)-2-甲基丙酸钠盐的晶型
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
CN106883169A (zh) * 2017-04-01 2017-06-23 浙江永宁药业股份有限公司 一种3‑(4‑氰基‑1‑萘基)‑4‑卤代吡啶的制备方法及其应用
CN108659000B (zh) * 2017-05-03 2020-03-31 成都海创药业有限公司 杂环化合物及其制备方法
WO2019069973A1 (ja) * 2017-10-04 2019-04-11 日本たばこ産業株式会社 含窒素ヘテロアリール化合物およびその医薬用途
CN107955029B (zh) * 2017-12-07 2020-08-11 成都美域高制药有限公司 一种雷西纳德的制备方法
CN108069940B (zh) * 2017-12-20 2021-04-30 广东赛烽医药科技有限公司 硫代乙酸化合物、组合物及其应用
CN108084153A (zh) * 2017-12-20 2018-05-29 广东赛烽医药科技有限公司 吡啶基硫代乙酸化合物、组合物及其应用
CN108440397B (zh) * 2018-03-06 2020-06-05 南方医科大学 3-(萘-1-甲基取代)吡啶衍生物及其合成方法和应用
WO2019183835A1 (en) * 2018-03-28 2019-10-03 Inventisbio Shanghai Ltd. Novel salt forms of urat-1 inhibitors
CN109608432B (zh) * 2018-12-17 2022-10-11 江苏艾立康医药科技有限公司 作为urat1抑制剂的噻吩类衍生物
JP2022541482A (ja) 2019-07-16 2022-09-26 アストラゼネカ・アクチエボラーグ ベリヌラドを含む用量ダンピング耐性医薬組成物
CN114315705B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与用途
CN114621136B (zh) * 2020-12-09 2023-11-07 江苏正大清江制药有限公司 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用
AR124985A1 (es) * 2021-03-01 2023-05-24 Orion Corp Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona
EP4301749A1 (en) * 2021-03-01 2024-01-10 Orion Corporation Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor
CN115385854B (zh) * 2021-05-19 2024-04-09 江苏正大清江制药有限公司 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用
CN113979931B (zh) * 2021-10-08 2023-06-13 南方医科大学 一种吡啶3-胺衍生物及其制备方法和应用
CN114214361A (zh) * 2022-01-07 2022-03-22 中国农业科学院兰州兽医研究所 一种urat1人源化小鼠模型的构建方法及其应用
CN117362223A (zh) * 2023-09-14 2024-01-09 河北远征药业有限公司 一种4-巯基吡啶的制备方法
WO2025060752A1 (zh) * 2023-09-19 2025-03-27 湘北威尔曼制药股份有限公司 一种硫醚衍生物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE642046A (enExample) * 1963-01-03
ES475100A1 (es) * 1977-11-21 1979-12-01 Hoechst Ag Un metodo para preparar acidos 1,2-benzisoxazoloxiaceticos
JPS6054310B2 (ja) 1979-02-21 1985-11-29 三井東圧化学株式会社 ピリダジン誘導体と農園芸用殺菌剤
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5051442A (en) 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
DE122008000051I1 (de) 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
JPH06234732A (ja) * 1992-09-10 1994-08-23 Banyu Pharmaceut Co Ltd 置換アセトアミド誘導体
CA2105617A1 (en) * 1992-09-10 1994-03-11 Yoshikazu Iwasawa Substituted acetamide derivatives
US5344651A (en) 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
US6492372B1 (en) * 1999-01-22 2002-12-10 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
GB0108339D0 (en) 2001-04-03 2001-05-23 Syngenta Participations Ag Organics compounds
WO2006026356A2 (en) 2004-08-25 2006-03-09 Ardea Biosciences, Inc. S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
CA2608821A1 (en) 2005-06-15 2006-12-28 Shibo Jiang Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
US20070099970A1 (en) * 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
US20090131384A1 (en) 2006-03-22 2009-05-21 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
HRP20130900T1 (hr) * 2007-04-11 2013-11-08 Kissei Pharmaceutical Co., Ltd. Derivat (aza)indola i njegova uporaba u medicinske svrhe
BRPI0819847B1 (pt) * 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CN102186832B (zh) 2008-09-04 2014-04-02 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
JP2012527475A (ja) * 2009-05-20 2012-11-08 アルディア バイオサイエンス,インク. 尿酸値を調節するための化合物、組成物及び方法
US20110082120A1 (en) 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
BR112012032193A2 (pt) 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
CA2852490A1 (en) * 2011-11-03 2013-05-10 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound to reduce serum uric acid levels

Similar Documents

Publication Publication Date Title
HRP20140391T1 (hr) Spojevi i pripravci tioacetata, te postupci uporabe
JP2012184234A5 (enExample)
JP2014532726A5 (enExample)
JP2017524704A5 (enExample)
JP2014532647A5 (enExample)
RU2018120242A (ru) Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов
JP2013528650A5 (enExample)
NO20070155L (no) 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft
JP2017528503A5 (enExample)
JP2011520965A5 (enExample)
JP2013087119A5 (enExample)
JP2015057436A5 (enExample)
PH12018500261B1 (en) Azole benzene derivative
JP2016540749A5 (enExample)
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
CN109790155A (zh) 噻吩化合物及其合成方法和其在医药上的应用
JP2016520133A5 (enExample)
JP2014532760A5 (enExample)
JP2017511377A5 (enExample)
JP2015521156A5 (enExample)
CY1124383T1 (el) Προληψη ή αγωγη παθησης ουρικου οξεος ή ποδαγρας
CN114072404A (zh) Ret选择性抑制剂及其制备方法和用途
WO2013057251A3 (en) Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2008513510A5 (enExample)
JP2019507791A5 (enExample)